Last reviewed · How we verify

bupivacaine and methylprednisolone

Bursa Yuksek Ihtisas Training and Research Hospital · FDA-approved active Small molecule Quality 5/100

bupivacaine and methylprednisolone is a Small molecule drug developed by Bursa Yuksek Ihtisas Training and Research Hospital. It is currently FDA-approved. Also known as: suprascapular nerve block.

At a glance

Generic namebupivacaine and methylprednisolone
Also known assuprascapular nerve block
SponsorBursa Yuksek Ihtisas Training and Research Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bupivacaine and methylprednisolone

What is bupivacaine and methylprednisolone?

bupivacaine and methylprednisolone is a Small molecule drug developed by Bursa Yuksek Ihtisas Training and Research Hospital.

Who makes bupivacaine and methylprednisolone?

bupivacaine and methylprednisolone is developed and marketed by Bursa Yuksek Ihtisas Training and Research Hospital (see full Bursa Yuksek Ihtisas Training and Research Hospital pipeline at /company/bursa-yuksek-ihtisas-training-and-research-hospital).

Is bupivacaine and methylprednisolone also known as anything else?

bupivacaine and methylprednisolone is also known as suprascapular nerve block.

What development phase is bupivacaine and methylprednisolone in?

bupivacaine and methylprednisolone is FDA-approved (marketed).

Related